secwatch.observer — SEC 8-K summary
======================================

Issuer:     LadRx Corp (—)
CIK:        0000799698
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001493152-23-022337
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LadRx sells aldoxorubicin and arimoclomol royalty rights to XOMA for $5M upfront; up to $6M more
--------------------------------------------------------------------------------

- Gross proceeds $5M at closing; potential $6M milestones: $1M on FDA acceptance of arimoclomol NDA, $1M on first sale, $4M on aldoxorubicin FDA approval.
- XOMA acquires all milestone and royalty payments from ImmunityBio and Zevra, net of existing obligations.
- Proceeds to advance lead candidate LADR-7 toward IND filing; 12 months of final IND-enabling work estimated.
- Transaction structured as non-dilutive financing; Roth Capital Partners acted as placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/0001493152-23-022337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-022337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer